A new clinical staging system for esophageal cancer to predict survival after definitive chemoradiation or radiotherapy

2018 ◽  
Vol 31 (11) ◽  
Author(s):  
J Chen ◽  
Y Lin ◽  
W Cai ◽  
T Su ◽  
B Wang ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Staging System ◽  
Clinical Staging ◽  
Definitive Chemoradiation ◽  
Clinical Staging System

Revision of the clinical staging system for cancer of the larynx

Cancer ◽  
1973 ◽  
Vol 31 (1) ◽  
pp. 72-80 ◽  
Author(s):  
Robert R. Smith ◽  
Ralph Caulk ◽  
Edgar Frazell ◽  
Paul H. Holinger ◽  
William S. Maccomb ◽  
...  
Keyword(s):  
Staging System ◽  
Clinical Staging ◽  
Clinical Staging System

A proposed clinical staging system for obesity

2009 ◽  
Vol 33 (3) ◽  
pp. 289-295 ◽  
Author(s):  
A M Sharma ◽  
R F Kushner
Keyword(s):  
Staging System ◽  
Clinical Staging ◽  
Clinical Staging System

A TNM-Based Clinical Staging System of Ocular Adnexal Lymphomas

2009 ◽  
Vol 133 (8) ◽  
pp. 1262-1267 ◽  
Author(s):  
Sarah E. Coupland ◽  
Valerie A. White ◽  
Jack Rootman ◽  
Bertil Damato ◽  
Paul T. Finger
Keyword(s):  
Prognostic Significance ◽  
Staging System ◽  
Clinical Staging ◽  
Disease Extent ◽  
Non Hodgkin Lymphoma ◽  
Ann Arbor ◽  
Data Points ◽  
Specific Factors ◽  
Clinical Staging System ◽  
User Friendly

Abstract Context.—The ocular adnexal lymphomas (OAL) arise in the conjunctiva, orbit, lacrimal gland, and eyelids. To date, they have been clinically staged using the Ann Arbor staging system, first designed for Hodgkin and later for nodal, non–Hodgkin lymphoma. The Ann Arbor system has several shortcomings, particularly when staging extranodal non– Hodgkin lymphomas, such as OAL, which show different dissemination patterns from nodal lymphomas. Objective.—To describe the first TNM-based clinical staging system for OAL. Design.—Retrospective literature review. Results.—We have developed, to our knowledge, the first American Joint Committee on Cancer–International Union Against Cancer TNM-based staging system for OAL to overcome the limitations of the Ann Arbor system. Our staging system defines disease extent more precisely within the various anatomic compartments of the ocular adnexa and allows for analysis of site-specific factors not addressed previously. It aims to facilitate future studies by identifying clinical and histomorphologic features of prognostic significance. This system is for primary OAL only and is not intended for intraocular lymphomas. Conclusions.—Our TNM-based staging system for OAL is a user-friendly, anatomic documentation of disease extent, which creates a common language for multicenter and international collaboration. Data points will be collected with the aim of identifying biomarkers to be incorporated into the staging system.

A rational clinical staging system for childhood rhabdomyosarcoma.

1984 ◽  
Vol 2 (2) ◽  
pp. 135-139 ◽  
Author(s):  
S S Donaldson ◽  
J A Belli
Keyword(s):  
Natural History ◽  
Therapeutic Strategy ◽  
Tumor Volume ◽  
Staging System ◽  
Clinical Staging ◽  
Tumor Node Metastasis ◽  
Node Metastasis ◽  
History Of ◽  
Clinical Staging System ◽  
Childhood Rhabdomyosarcoma

There is a need for a rational and useful staging system for childhood rhabdomyosarcoma that predicts prognosis based on the biology and natural history of the disease. Important factors to consider are age, histology, tumor volume, extent of invasion, and lymphatic involvement. A clinical staging system based on a classical tumor/node/metastasis status, and which accounts for natural history as a function of site of primary, local invasion, and lymphatic or hematogenous metastases is presented. This staging system eliminates the requirement that stage is assigned following an initial therapeutic strategy and removing the implication that prognosis is determined by that strategy.

scholarly journals Clinical staging system for hairy-cell leukemia

Blood ◽  
1982 ◽  
Vol 60 (3) ◽  
pp. 571-577 ◽  
Author(s):  
J Jansen ◽  
J Hermans
Keyword(s):  
Hairy Cell Leukemia ◽  
Staging System ◽  
Hemoglobin Level ◽  
Clinical Staging ◽  
Costal Margin ◽  
Hairy Cell ◽  
Cell Leukemia ◽  
Staging Systems ◽  
Clinical Staging System ◽  
Choice Of Therapy

Abstract To find a clinical staging system for patients with hairy cell leukemia, 391 patients contributed by 22 centers were analyzed using the proportional hazard survival model. Attention was paid to nonsplenectomized patients to find a staging system to predict the survival length at the time of diagnosis. On the basis of hemoglobin level and spleen size at the time of diagnosis, 3 stages could be distinguished with significantly different prognoses (stages I-III). In addition, we addressed the question of splenectomy to identify those patients who benefit from the operation. Using arbitrary, but clinically relevant, criteria to call the operation beneficial, splenectomy appears to be indicated for patients with large spleens (greater than or equal to 4 cm under costal margin) or with smaller, but palpable, spleens when anemia (Hb less than 12 g/dl) is present. The third question concerned the splenectomized patients. To indicate the patients who have a poor postsplenectomy survival, a staging system was developed on the basis of hemoglobin level and number of neutrophils at 2–3 mo after the operation (stages A-C). The validity of the two staging systems was supported by the results of an analysis of an independent test series of patients. These staging systems may be helpful for the choice of therapy and in the planning of clinical trials in patients with hairy-cell leukemia.

scholarly journals Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon?

Cancer ◽  
2002 ◽  
Vol 95 (6) ◽  
pp. 1334-1345 ◽  
Author(s):  
Andrea Baur ◽  
Axel Stäbler ◽  
Dorothea Nagel ◽  
Rolf Lamerz ◽  
Reiner Bartl ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Staging System ◽  
Clinical Staging ◽  
Resonance Imaging ◽  
Clinical Staging System

Re: Improved Clinical Staging System Combining Biopsy Laterality and TNM Stage for Men With T1c and T2 Prostate Cancer: Results From the Search Database

2004 ◽  
Vol 171 (3) ◽  
pp. 1246-1247
Author(s):  
Mark K. Buyyounouski ◽  
Eric M. Horwitz ◽  
Alexandra L. Hanlon ◽  
Robert G. Uzzo ◽  
Alan Pollack
Keyword(s):  
Prostate Cancer ◽  
Staging System ◽  
Tnm Stage ◽  
Clinical Staging ◽  
Clinical Staging System
Sign in / Sign up

Export Citation Format

Share Document